Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;8(4):580-590.
doi: 10.1007/s13193-016-0543-z. Epub 2016 Jul 27.

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer

Yuji Miyamoto  1   2 , Wu Zhang  1 , Heinz-Josef Lenz  1
Affiliations
Review

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer

Yuji Miyamoto et al. Indian J Surg Oncol. 2017 Dec.

Abstract

Over the last 20 years, median survival for patients with metastatic colorectal cancer (CRC) has remarkably improved from about 12 to over 30 months, mainly because of the development of new agents and patient selection using predictive biomarkers. However, the identification of the most effective treatment for an individual patient is still a challenge. Molecular profiling of CRC has made great progress, but it is limited by tumor heterogeneity and absence of driver mutation. However, RAS, BRAF, and microsatellite instability are validated biomarker recommended by NCCN and ESMO. In this review, we discuss recent advances and future developments.

Keywords: Biomarker; Chemotherapy; Colorectal cancer; Molecular pathway; Personalized therapy; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

HJ Lenz has received honoraria from Merck Serono, Roche, Celgene, Bayer, and Boehringer Ingelheim. The other authors have no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–1618. doi: 10.1056/NEJMoa1403108. - DOI - PubMed
    1. Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14:1278–1286. doi: 10.1016/S1470-2045(13)70490-X. - DOI - PubMed
    1. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–1075. doi: 10.1016/S1470-2045(14)70330-4. - DOI - PubMed
    1. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337. doi: 10.1038/nature11252. - DOI - PMC - PubMed
    1. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–1356. doi: 10.1038/nm.3967. - DOI - PMC - PubMed

LinkOut - more resources